Telum Therapeutics SL has completed an €18 million (US$24 million) series A financing to advance its lead program targeting hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by the multidrug-resistant gram-negative pathogen Acinetobacter baumannii.
It is known that bacterial cells exchange biological matter, but it is not clear whether bacteria can exchange functional proteins. In a recent paper published in Science on June 25, 2026, researchers from Baylor College of Medicine and their collaborators investigated horizontal protein transfer between bacteria, specifically between protein-donor Escherichia coli and protein-receiving E. coli that could turn into persister cells and tolerate lethal antibiotic doses or a stressful environment.
At the World Vaccine Congress this week, Longhorn Vaccines & Diagnostics LLC presented the preclinical characterization of LHNVD-501, a half-life-extended, humanized IgG monoclonal antibody (mAb) targeting peptidoglycan (PGN). PGN is a conserved structural component shared across bacterial species and an upstream driver of sepsis, as well as metabolic disease, autoimmune disorders and neurodegeneration.
Researchers from the Indian Institute of Technology Bombay have reported the preclinical development of a new synthetic antimicrobial class incorporating organic metallophores, which yielded two optimized leads – VY-AD-4-11-6 and VY-AD-4-22-6 – from a 30-compound SAR series.
Smartbax GmbH has in-licensed a new compound class from the antibacterial portfolio of Aicuris Anti-infective Cures AG to expand its proprietary pipeline of small-molecule antibiotics.
Antibiotics specialist Bioversys AG has sealed a potential CHF529 million (US$667.5 million) deal with Shionogi Co. Ltd., in which they will work together on novel ansamycins for treating multidrug-resistant lung infections caused by non-tuberculous mycobacteria.
Antibiotics specialist Bioversys AG has sealed a potential CHF529 million (US$667.5 million) deal with Shionogi Co. Ltd., in which they will work together on novel ansamycins for treating multidrug-resistant lung infections caused by non-tuberculous mycobacteria.
Antibiotics specialist Bioversys AG has sealed a potential CHF529 million (US$667.5 million) deal with Shionogi Co. Ltd., in which they will work together on novel ansamycins for treating multidrug-resistant lung infections caused by non-tuberculous mycobacteria.
Writing in Nature, researchers from China Pharmaceutical University and Shandong University have revealed the discovery of a new polyene antifungal antibiotic, mandimycin.
